Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Puma Biotechnology, Inc. (PBYI : NSDQ)
 
 • Company Description   
Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also approved in the European Union. Nerlynx in combination with Roche's Xeloda was approved?by the Food and Drug Administration for third-line HER2-positive metastatic breast cancer. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations as well as other types of cancers are currently underway. A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers. Puma markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.

Number of Employees: 196

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.88 Daily Weekly Monthly
20 Day Moving Average: 415,587 shares
Shares Outstanding: 44.97 (millions)
Market Capitalization: $84.55 (millions)
Beta: 1.07
52 Week High: $11.95
52 Week Low: $1.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -32.86% -26.43%
12 Week -14.55% -7.28%
Year To Date -38.16% -26.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10880 WILSHIRE BOULEVARD SUITE 2150
-
LOS ANGELES,CA 90024
USA
ph: 424-248-6500
fax: 424-248-6501
ir@pumabiotechnology.com http://www.pumabiotechnology.com
 
 • General Corporate Information   
Officers
Alan H. Auerbach - President & Chief Executive Officer
Alan H. Auerbach - Director
Maximo Nougues - Director
Allison Dorval - Director
Michael P. Miller - Director

Peer Information
Puma Biotechnology, Inc. (CORR.)
Puma Biotechnology, Inc. (RSPI)
Puma Biotechnology, Inc. (CGXP)
Puma Biotechnology, Inc. (BGEN)
Puma Biotechnology, Inc. (GTBP)
Puma Biotechnology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74587V107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 44.97
Most Recent Split Date: (:1)
Beta: 1.07
Market Capitalization: $84.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.04 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 47.00
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.42
EPS Growth
vs. Year Ago Period: -120.00%
vs. Previous Quarter: -180.00%
Sales Growth
vs. Year Ago Period: -53.46%
vs. Previous Quarter: -17.51%
ROE
03/31/22 - -912.99
12/31/21 - -357.74
09/30/21 - -665.45
ROA
03/31/22 - -20.62
12/31/21 - -11.98
09/30/21 - -19.53
Current Ratio
03/31/22 - -
12/31/21 - 1.28
09/30/21 - 1.18
Quick Ratio
03/31/22 - -
12/31/21 - 1.21
09/30/21 - 1.12
Operating Margin
03/31/22 - -24.42
12/31/21 - -11.49
09/30/21 - -19.29
Net Margin
03/31/22 - -24.42
12/31/21 - -11.49
09/30/21 - -19.29
Pre-Tax Margin
03/31/22 - -
12/31/21 - -11.38
09/30/21 - -19.14
Book Value
03/31/22 - -
12/31/21 - -0.06
09/30/21 - -0.27
Inventory Turnover
03/31/22 - -
12/31/21 - 8.59
09/30/21 - 9.64
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©